This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F07%3A00001574%21RIV08-MZ0-00023001/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F07%3A00001574%21RIV08-MZ0-00023001
rdf:type
skos:Concept n15:Vysledek
dcterms:description
OBJECTIVES: Arterial stiffening and endothelial dysfunction are hallmarks of aging, and advanced glycation endproducts (AGE) may contribute to these changes. We tested the hypothesis that AGE crosslink breakers enhance endothelial flow-mediated dilation (FMD) in humans and examined the potential mechanisms for this effect. METHODS: Thirteen adults (nine men, aged 65 +/- 2 years) with isolated systolic hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure < 90 mmHg or pulse pressure > 60 mmHg) on stable antihypertensive therapy were studied. Subjects received placebo (2 weeks) then oral alagebrium (ALT-711; 210 mg twice a day for 8 weeks). Subjects and data analyses were blinded to treatment. Arterial stiffness was assessed by carotid augmentation index (AI) and brachial artery distensibility (ArtD) using applanation tonometry and Doppler echo, and endothelial function by brachial FMD. Serum markers of collagen metabolism and vascular inflammation were asse OBJECTIVES: Arterial stiffening and endothelial dysfunction are hallmarks of aging, and advanced glycation endproducts (AGE) may contribute to these changes. We tested the hypothesis that AGE crosslink breakers enhance endothelial flow-mediated dilation (FMD) in humans and examined the potential mechanisms for this effect. METHODS: Thirteen adults (nine men, aged 65 +/- 2 years) with isolated systolic hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure < 90 mmHg or pulse pressure > 60 mmHg) on stable antihypertensive therapy were studied. Subjects received placebo (2 weeks) then oral alagebrium (ALT-711; 210 mg twice a day for 8 weeks). Subjects and data analyses were blinded to treatment. Arterial stiffness was assessed by carotid augmentation index (AI) and brachial artery distensibility (ArtD) using applanation tonometry and Doppler echo, and endothelial function by brachial FMD. Serum markers of collagen metabolism and vascular inflammation were asse tuhnutí tepenné stěny, endoteliální dysfunkce, stárnutí, koncové produky pokročilé glykace
dcterms:title
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension %22Crosslink breaker%22 (dosl. ničitel příčné vazby) koncového produktu pokročilé glykace (alagebrium) zlepšuje u pacientů s izolovanou systolickou hypertenzí funkci endotelu Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
skos:prefLabel
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension %22Crosslink breaker%22 (dosl. ničitel příčné vazby) koncového produktu pokročilé glykace (alagebrium) zlepšuje u pacientů s izolovanou systolickou hypertenzí funkci endotelu
skos:notation
RIV/00023001:_____/07:00001574!RIV08-MZ0-00023001
n3:strany
577-583
n3:aktivita
n7:N
n3:aktivity
N
n3:cisloPeriodika
3
n3:dodaniDat
n9:2008
n3:domaciTvurceVysledku
n13:4066332
n3:druhVysledku
n11:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
408648
n3:idVysledku
RIV/00023001:_____/07:00001574
n3:jazykVysledku
n4:eng
n3:klicovaSlova
cardiology
n3:klicoveSlovo
n10:cardiology
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[FC287222E004]
n3:nazevZdroje
Journal of Hypertension
n3:obor
n16:FA
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
7
n3:rokUplatneniVysledku
n9:2007
n3:svazekPeriodika
25
n3:tvurceVysledku
Kass, D. A. Capriotti, A. Zieman, S. J. Coretti, M. C. Melenovský, Vojtěch Gerstenblith, G. Clattenburg, L.
s:issn
0263-6352
s:numberOfPages
7